Borges Luis 4
4 · Century Therapeutics, Inc. · Filed Mar 23, 2023
Insider Transaction Report
Form 4
Borges Luis
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2023-03-21$1.03/sh+63,616$65,524→ 107,366 total - Sale
Common Stock
2023-03-21$3.77/sh−63,616$239,870→ 43,750 total - Exercise/Conversion
Common Stock
2023-03-22$1.03/sh+65,698$67,669→ 109,448 total - Sale
Common Stock
2023-03-22$3.72/sh−65,698$244,640→ 43,750 total - Exercise/Conversion
Common Stock
2023-03-23$1.03/sh+220,930$227,558→ 264,680 total - Sale
Common Stock
2023-03-23$3.55/sh−15,597$55,369→ 249,083 total - Exercise/Conversion
Stock Option (right to buy)
2023-03-21−63,616→ 294,080 totalExercise: $1.03Exp: 2029-07-17→ Common Stock (63,616 underlying) - Exercise/Conversion
Stock Option (right to buy)
2023-03-22−65,698→ 228,382 totalExercise: $1.03Exp: 2029-07-17→ Common Stock (65,698 underlying) - Exercise/Conversion
Stock Option (right to buy)
2023-03-23−220,930→ 7,452 totalExercise: $1.03Exp: 2029-07-17→ Common Stock (220,930 underlying)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $3.935, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.57 to $3.79, inclusive.
- [F3]The option vests 25% on April 1, 2020, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer.